Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Do We Need To Re-Think Standard Treatment For Traumatic Brain Injury?
Traumatic brain injury - not heart disease, stroke or cancer - is the number one cause of death and disability in people under 45. Each year, some 1.5 million Americans, including soldiers, athletes, the elderly and children, sustain head injuries, and nearly half of them will be hospitalized and treated in an emergency room or intensive care unit.
generic viagra online
Shanghai To Relax One-Child Policy As China Faces Aging Population, Shrinking Work Force
Nearly three decades after China implemented its one-child policy, the city of Shanghai is planning to encourage young couples to have a second child in an effort to address the country"s aging population and shrinking work force, the New York Times reports. The city"s plan is the most public effort made by the government to counteract a program that is "considered both a tremendous success and a terrible failure," the Times reports. The policy has managed to keep population growth under control but also has led to forced abortions, according to the Times.The country is not abandoning the one-child policy, which applies mostly to residents in urban areas. Rather, the government is allowing more exceptions to the rule, with Shanghai -- where about 22% of its 20 million residents are older than age 60 -- leading the effort. China as a whole faces a similar problem seen in Shanghai, the Times reports. About 8% of the country"s population was older than age 65 in 2006. That figure is expected to increase threefold by 2050 to about 322 million people, or nearly 25% of the population, according to the United Nations.In Friday"s issue of China Daily, Xie Lingli, director of the Shanghai Population and Family Planning Commission, was quoted as saying, "We advocate eligible couples to have two kids because it can help reduce the proportion of the aging people and alleviate a work force shortage in the future." City officials plan to visit homes, pass out leaflets, and offer counseling and financial incentives, the Times reports. Current exceptions to the one-child policy are in place for ethnic minorities and rural residents, who can have a second child if the first child is a girl. Couples made up of two parents who have no siblings have always been allowed to have a second child and are now being encouraged to do so (Barboza, New York Times, 7/24).
News of the day
Sodexo's Training Strategy And Vocational Rehabilitation Program Recognized
Sodexo (PARIS:SW) (OTCBB:SDXAY) received two awards at the inaugural Professional Training Evening held May 25 in Paris: the "Best Training Strategy" award and the Favorites Award for "Successful vocational rehabilitation." The culmination of a 75-company competition, the event was organized jointly by France"s National Association of Human Res Directors (ANDRH), Professional Training Federation (FFP) and Association of Trainers and Training Managers (GARF).
Nutrition

Bayer Completes Phase II Study On BAY 94-9172 In Alzheimer's Disease Diagnostic Imaging Using Positron Emission Tomography (PET)

Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer"s disease compared to healthy volunteers. BAY 94-9172 binds to the beta amyloid protein in the brain, a pathological hallmark of Alzheimer"s disease. The data is being analyzed and results will be presented at this years International Conference on Alzheimer"s Disease (ICAD) in Vienna. Additional information on BAY 94-9172 and related research & development programs will be presented at the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 - 17, 2009. "Beta amyloid has been proven to be a pathological hallmark of Alzheimer"s disease and it is accumulated in the brain very early in the course of the disease. Currently, the detection of this protein and, thus, the definitive diagnosis of Alzheimer"s disease is only possible upon post-mortem," said Thomas Balzer, M.D., Head of Global Clinical Development Therapeutic Area Diagnostic Imaging. "Thus an in-vivo imaging method would be clinically very useful as it could help in the differentiation between different dementia forms and either exclude Alzheimer"s disease or make it very likely. There is a high unmet medical need for a better and earlier differentiation between the various dementia forms and especially of Alzheimer"s disease. We hope that BAY 94-9172 can contribute to this for the patient"s benefit because an earlier and more accurate diagnosis allows for optimized care and treatment options," he added. Bayer Schering Pharma has extended its Phase II program to further expand the number of imaged individuals and will also begin its pivotal Phase III global clinical development program of BAY 94-9172 in the second half of this year. Interesting contributions at the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 - 17, 2009 are listed below: Test-retest variability of [18F]BAY94-9172 PET in Alzheimer"s disease and normal ageing - Authors: Rowe, C.C.(1); Pejovska, S.1; Mulligan, R.S.(1); Chan, G.(1); Jones, G.(1); Fels, L.(2); Kusi, H.(2); Reininger, C.(2); Rhode, B.(2); Putz, B.(2); O"Keefe, G.(1); Masters, C.L.(3); Villemagne, V.L.(1) (1)Austin Hospital, Melbourne, VIC, Australia; (2)Bayer Schering Pharma AG, Berlin, Germany; (3)The Mental Health Research Institute of Victoria, Melbourne, VIC, Australia. - Scientific poster presentation at Neurology Posters, Poster Session I: Multimodality and Non-Radioactive Molecular Imaging, Educational Exhibits, Cardiovascular & Neuroscience Track Posters, Monday, June 15, 2:30 PM - 3:15 PM, Exhibit Hall E/F Kinetic modeling of BAY94-9172 binding to Ãÿ-amyloid in human brains using PET data - Authors: Becker, G.(1); Barthel, H.(1); Luthardt, J.(1); Patt, M.(1); Hammerstein, E.(2); Eggers, B.(3); Reininger, C.(4); Rohde, B.(4); Hegerl, U.(2); Gertz, H.-J.(2); Sabri, O.(1) Departments of (1)Nuclear Medicine and (2)Psychiatry, University of Leipzig, (3)Arzneimittelforschung Leipzig Ltd., (4)Bayer Schering Pharma AG, Berlin, Germany - Oral presentation at Dementia II Session: Tracer Properties, Evaluation Methods, Tuesday, June 16, 12:30 PM - 2 PM, Room 701A Quantification of the radiation risk caused by [F18]BAY94-9172, a new PET tracer for detection of cerebral beta-amyloid plaques - Authors: Sattler, B.(1); Seese, A.(1); Barthel, H.(1); Patt, M.(1); Schildan, A.(1); Zollmann, F.(2); Reininger, C.(2); Rohde, B.(2); Eggers, B.(4); Gertz, H.-J.(3); Hegerl, U.(3); Sabri, O.(1) (1)University Hospital Leipzig, Dept. of Nuclear medicine; (2)Bayer Schering Pharma AG, Berlin; (3)University Hospital Leipzig, Dept. of Psychiatry; (4)Pharmaceutical Research Leipzig GmbH - Scientific poster presentation at Dosimetry/ISRTRD Posters, Poster session IV: Radiopharmaceutical Chemistry Track Posters,Tuesday, June 16 , 5:15 PM - 6:00 PM, Exhibit Hall E/F Comparisons of Animal-Human Translated and Human 18F-BAY94-9172 Amyloid Radiation Dosimetry - Authors: O"Keefe, G.J.(1); Saunder, T.H.(1); Gong, S.(1); Pathmaraj, K.U.(1); Tochon-Danguy, H.T.(1); Villemagne, V.(1); Dyrks, T.(2); Dinkelborg, L.(2); Holl, G.(2); Rowe, C.C.(1) (1)Centre for PET, Austin Hospital, Heidelberg, Australia; (2)Bayer Schering Pharma AG, Berlin, Germany - Scientific poster presentation at Dosimetry/ISRTRD Posters: Posters Session IV: Radiopharmaceutical Chemistry Track Posters, Tuesday, June 16, 5:15 PM - 6:00 PM, Exhibit Hall E/F About BAY 94-9172 BAY 94-9172 is an inlicensed (18)F-labeled PET tracer and binds to beta amyloid, a protein that accumulates in the brain and that is considered being a pathological hallmark of Alzheimer"s disease. Alzheimer"s disease is a neuro-degenerative disease and most common cause of severe dementia in the age group over 60 years which may also lead to death. Imaging with (18)F-BAY 94-9172 should offer the possibility to support an early detection of Alzheimer"s disease with an in-vivo imaging method. BAY 94-9172 is currently in clinical development. About the Phase II study The open-label, nonrandomized, multi-center Phase II study with independent, blinded image evaluation was performed to determine the sensitivity and specificity of the visual assessment of BAY 94-9172 (AV1/ZK) positron emission tomography (PET) images in detecting/excluding cerebral beta amyloid in patients with probable Alzheimer"s disease (AD) compared to healthy volunteers (HV). A total of 18 study centers in 4 countries (Australia, Germany, USA, Switzerland) recruited a total of 221 individuals (150 of which were imaged with BAY 94-9172) into the phase II trial in less than 8 months. About Alzheimer"s Disease Alzheimer"s disease affects an estimated 4.5 million people in the United States alone. That number has doubled since 1980 and is expected to exceed 12 million people by 2050 as the U.S. population ages. Worldwide representative epidemiological surveys estimate that 24.3 million people suffer from dementia today with about 4.6 million new cases every year. The number of people affected will double every 20 years to an estimated 81.1 million by 2040. Bayer HealthCare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009